Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24 July 2014
biogen-logo-big

US biotech firm Biogen Idec (Nasdaq: BIIB) said that the European Commission has approved its subcutaneous injectable Plegridy (peginterferon beta-1a) for the treatment of adults with relapsing-remitting multiple sclerosis.

Biogen Idec shares climbed 11.2% to $337.60 Wednesday, but that was as much to do with the reporting of strong second-quarter financial results (see separate story yesterday)

This follows a positive recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use in May. The decision is supported by a study of 1516 patients with relapsing-remitting multiple sclerosis, randomised to receive the drug every two or four weeks, or to receive a placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical